Final data from Open-Label studies of Cinryze in patients with HAE now available

ViroPharma Incorporated (Nasdaq: VPHM) today announced the availability of final data from Open-Label studies of Cinryze™ (C1 Esterase Inhibitor [Human]) in preventing and treating attacks of hereditary angioedema (HAE) on the U.S. National Institutes of Health's online clinical trial registry, www.clinicaltrials.gov. The data from the CHANGE 3 prophylaxis study are available now; the data from the CHANGE 2 acute treatment study will be available at the same website in the coming weeks.  The company expects the complete data set to be presented at a scientific meeting later this year and in subsequent publications in peer-reviewed journals.

Cinryze was approved by the U.S. Food and Drug Administration in October 2008 for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE.  Cinryze is not approved in the U.S. for acute treatment of attacks.    

"We are excited about the strength of these data in support of the efficacy and safety of Cinryze, and are happy to see them available online," commented Colin Broom, M.D., ViroPharma's chief scientific officer.  "Our open label experience with the therapy, outside the confines of controlled pivotal clinical studies, has shown that Cinryze therapy can change the lives of HAE patients and their families. For example, prophylaxis with Cinryze in the open label prevention study dramatically reduced the median frequency of attacks from three times per month to less than three attacks per year.  Our goal as a company is to improve the lives of the patients suffering from HAE, and it is clear that Cinryze accomplishes that goal for patients who choose prophylaxis against their HAE attacks as their means to regain control of their lives."

Open-Label C1 Esterase Inhibitor for the Prevention of Acute HAE Attacks

The CHANGE 3 study was performed to evaluate the safety and efficacy of prophylactic use of Cinryze for the prevention of attacks of HAE.  One hundred forty six (146) HAE patients were enrolled in this study and were included in the analysis of the primary efficacy outcome measure.  The vast majority of the patients enrolled in the study have transitioned to commercial Cinryze. Seventy-nine (79) patients completed the study; most of those not completing the study did so because they transitioned to commercial Cinryze before the end of the study.  Per protocol, patients received 1,000U of Cinryze administered intravenously every three to seven days.

The primary efficacy outcome measure was the frequency of all HAE attacks that occurred during prophylaxis with Cinryze.  Prior to initiating prophylactic therapy with Cinryze, patients enrolled in the study had a median of 3.00 HAE attacks per month. During prophylaxis with Cinryze, over a median of 244 days, enrolled patients had a median of 0.21 HAE attacks per month.

For patients that received Cinryze prophylaxis for at least one year, the degree of protection from HAE attacks was maintained over the one year period.

In this study, there were no serious adverse events (SAEs) considered related to Cinryze.  No subjects were discontinued from Cinryze due to an adverse event, and there were no adverse trends observed in vital signs. Among the 74 subjects tested, there were no subjects who had detectable anti-C1-INH antibodies following Cinryze administration.

Open-Label C1 Esterase Inhibitor for the Treatment of Acute HAE Attacks

The CHANGE 2 study was performed to evaluate the safety and efficacy of repeat use of Cinryze for treatment of attacks of HAE.  A total of 113 subjects were enrolled in the study; 101 subjects received Cinryze for treatment of one or more HAE attacks and were analyzed for efficacy.  Forty three (43) patients completed the study; the majority of the patients not completing the study did so because they transferred to the open-label prophylaxis study.  Per protocol, patients received 1,000U of Cinryze administered intravenously for treatment of HAE attacks.  If there was inadequate response to treatment within one hour after the first dose, a second 1,000U dose could be administered.

The primary efficacy outcome measure was the proportion of HAE attacks with substantial relief of the defining symptom within four hours of initial treatment with Cinryze. Substantial relief was attained in eighty seven (87) percent of attacks, when a conservative definition of response was applied so that all patients with incomplete data were considered treatment failures. Using a less conservative definition of substantial relief as either three consecutive reports of symptom improvement or improvement of the defining symptom followed by cessation of symptom assessments, ninety five (95) percent of HAE attacks were substantially relieved within four hours of initial treatment. Eighty-four (84) laryngeal attacks occurred during this study; none required intubation following treatment with Cinryze.

Data were also analyzed for patients who received Cinryze treatment for multiple attacks of HAE; there was no loss of effectiveness of Cinryze with subsequent repeat administration.

In this study, there were no serious adverse events (SAEs) considered related to Cinryze.  No subjects were discontinued from Cinryze due to an adverse event, and there were no adverse trends observed in vital signs. There was no evidence for the development of anti-C1-INH antibodies following repeated Cinryze administration.